Can a Mediterranean (or Italian) Diet Reduce Serum Antiphospholipid Antibodies in Dyslipidemic Blood Donors?

2015 ◽  
pp. 60-72
Author(s):  
G. Restori ◽  
L. Boiardi ◽  
R. Baricchi ◽  
R. Carbognani ◽  
G. Lab� ◽  
...  
Keyword(s):  
Antiphospholipid Antibodies ◽  
Blood Donors

Autoantibodies to Phospholipids and to the Coagulation Proteins in AIDS

1997 ◽  
Vol 77 (05) ◽  
pp. 0856-0861 ◽  
Author(s):  
N Abuaf ◽  
S Laperche ◽  
B Rajoely ◽  
R Carsique ◽  
A Deschamps ◽  
...  
Keyword(s):  
Lupus Erythematosus ◽  
Antiphospholipid Antibodies ◽  
Blood Donors ◽  
Heterogeneous Mixture ◽  
Systemic Lupus ◽  
Hematological Disorders ◽  
False Positive Test ◽  
Glycoprotein I ◽  
Coagulation Proteins ◽  
Hiv 1

SummaryIn HIV-1 infection, an increased prevalence of anticardiolipin autoantibodies (aCL) and lupus anticoagulant (LA) has been described. In order to see if these antibodies are isolated or, like in autoimmune diseases, associated with hematological disorders and with antibodies to other phospholipids and to proteins of coagulation, we investigated 3 groups of patients: 1. 342 HIV-1 infected patients, 2. 145 control patients including 61 systemic lupus erythematosus (SLE) patients, 58 patients with a connective tissue disease, 15 patients with stroke, 11 patients with syphilis and 3.100 blood donors. In HIV-1 infection antiprothrombin (aPrT) antibodies were present in 25% of patients, the prevalence of antiphosphatidylcholine antibodies (aPC) (50%) was almost as high as aCL (64%), and 39% had both antibodies. Absorption on liposomes of the latter revealed an heterogeneous mixture of aCL and aPC or cross-reacting antibodies. In contrast with SLE, anti-β2-glycoprotein I (4%), LA (1%), biological false positive test for syphilis (0.3%), thrombosis (p <0.001) were uncommon. In HIV-1 infection, antiphospholipid antibodies do not associate with features linked to them in SLE or syphilis.

Inter-laboratory Variability of Anti-β2-glycoprotein I Measurement

2002 ◽  
Vol 88 (07) ◽  
pp. 66-73 ◽  
Author(s):  
Inger Schousboe ◽  
Angela Tincani ◽  
Marielle Sanmarco ◽  
Tanja Kveder ◽  
Philippe de Moerloose ◽  
...  
Keyword(s):  
Antiphospholipid Antibodies ◽  
Blood Donors ◽  
Negative Sample ◽  
Large Variability ◽  
European Forum ◽  
Glycoprotein I ◽  
Sample Classification ◽  
Two Samples ◽  
Commercial Kits ◽  
Sample Measurement

SummaryInter-laboratory variability of anti-β2-glycoprotein I antibody measurements (IgG and IgM) was investigated in the frame of the European Forum on Antiphospholipid Antibodies and its Standardization Group. Twenty-eight samples from patients with autoimmune diseases, two samples from blood donors and a set of six calibrators obtained by dilution with normal plasma of a pool of patient samples were sent to 21 European centers. Six of them used commercial kits and the others home-made assays. Marked differences in the steepness of the calibration curves obtained with the calibrator provided were observed. The standard deviations of sample measurement were high. Cut-off of positivity varied from 7 to 90 Forum Units (FU) for IgG and from 10 to 138 FU for IgM, whereas the rate of positivity varied from 50 to 93% for IgG and from 13 to 70% for IgM. No clear relationship between cut-off values and positivity rate could be established for either isotype. Adopting a common cut-off did not markedly improve the overall agreement between centers in positive/negative sample classification. Because of the majority of low positive samples, excellent concordance between centers (as defined by kappa values from 0.8 and 1) occurred only in 13% of cases for IgG and in 6% of cases for IgM, because many selected samples were low-positive. Despite the large variability of anti-β2-glycoprotein I measurements between centers, the agreement on results with highand medium-positive samples was good.

Antibodies to Phosphatidylethanolamine as the only Antiphospholipid Antibodies Found in Patients with Unexplained Thromboses

2001 ◽  
Vol 85 (05) ◽  
pp. 800-805 ◽  
Author(s):  
Marie-Christine Alessi ◽  
Jean Robert Harle ◽  
Christophe Sapin ◽  
Marie-Françoise Aillaud ◽  
Stéphanie Gentile ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Infectious Diseases ◽  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Antiphospholipid Antibodies ◽  
Blood Donors ◽  
Systemic Lupus ◽  
A Site ◽  
Antiphosphatidylethanolamine Antibodies ◽  
Biological Variant

SummaryThe objective of this study was to assess the interest of antiphosphatidylethanolamine antibodies (aPE) in unexplained thrombosis (UT) defined as thrombotic episode without any of the main autoimmune and hereditary thrombophilic defects. Results from 98 UT were compared to those of (I) 142 patients with thrombophilia: 67 antiphospholipid syndrome (APS) and 75 hereditary hemostatic defects (HHD); (II) 110 patients without thrombosis: 60 with systemic lupus erythematosus (SLE) and 50 with infectious diseases (ID). As compared to controls (100 blood donors), aPE prevalence was significantly higher in both autoimmune contexts (APS: 43%; SLE: 40%, p <0.0001) and among non-autoimmune pathologies, only in UT (18%, p = 0.001) conversely to HHD (8%) or ID (10%). aPE prevalence in UT was not statistically different from that found in Primary APS (32%, p = 0.076) but lower than in Secondary APS (65%, p <0.005). In UT, aPE were mainly of IgM isotype like in Primary APS and they were found alone whereas in SLE they were always associated with classical anti-phospholipid antibodies. No significant association was found between any isotype of aPE and a site of thrombosis in UT as well as in APS. In conclusion, this study demonstrates an increase of the prevalence of aPE in patients with unexplained thrombosis. Thus, aPE investigation appears to be of interest in UT and their persistent presence could define a biological variant of APS.

Positive Direct Antiglobulin Test due to Antiphospholipid Antibodies in Normal Healthy Blood Donors

Vox Sanguinis ◽  
1997 ◽  
Vol 72 (3) ◽  
pp. 182-184 ◽  
Author(s):  
Nay Win ◽  
S.I.A.M. Islam ◽  
M.A. Peterkin ◽  
I.D. Walker
Keyword(s):  
Antiphospholipid Antibodies ◽  
Blood Donors ◽  
Direct Antiglobulin Test ◽  
Antiglobulin Test ◽  
Positive Direct

Revisiting the Phadia/EliA cut-off values for anticardiolipin and anti-β2-glycoprotein I antibodies: a systematic evaluation according to the guidelines

Lupus ◽  
2018 ◽  
Vol 27 (9) ◽  
pp. 1446-1454 ◽  
Author(s):  
M V Bor ◽  
I-L Søtang Jacobsen ◽  
J B Gram ◽  
J J Sidelmann
Keyword(s):  
International Society ◽  
Antiphospholipid Antibodies ◽  
Blood Donors ◽  
Solid Phase ◽  
Reference Intervals ◽  
Systematic Evaluation ◽  
Pregnancy Morbidity ◽  
Glycoprotein I ◽  
Different Populations ◽  
Positive Results

Background Phadia/EliA fluorescence enzyme immunoassays are widely used automated assays for anticardiolipin (aCL) and anti-β2-glycoprotein I (aβ2GPI) antibodies. To date, cut-off values for these assays have not been evaluated systematically and the evidence behind manufacturer’s recommended cut-off values is not clear. Objective To determine Phadia/EliA cut-off values for antiphospholipid antibodies (aPL) according to the procedures suggested by guidelines. Methods A total of 266 blood donors (135 females and 131 males) were included. The pre-handling and analysis of the samples were performed according to the International Society on Thrombosis and Hemostasis (ISTH) guideline for solid phase aPL assays. Cut-off values and corresponding 90% confidence intervals (CI) for each antibody were established and outliers were handled according to the Clinical and Laboratory Standards Institute (CLSI) guideline for reference intervals. Samples from 377 consecutive patients, referred to our thrombophilia center with evidence of thrombosis or pregnancy morbidity were included for aPL testing. Results The in-house 99th (97.5th) percentile cut-off values were 11 (8.7), 12 (6.9) 8.5 (5.0) AU/mL for aβ2GPI IgG, IgM and IgA, and 21 (13) GPL-U/mL and 41 (25) MPL-U/mL for aCL IgG and IgM, respectively. The prevalence of positive results (%) defined by these cut-off values in patients with evidence of thrombosis or pregnancy morbidity was 9.5 (12.2), 1.6 (2.9), and 7.0 (9.9), and 0.8 (3.8) for aβ2GPI IgG, IgM, and aCL IgG and IgM respectively. The use of in-house 99th percentile cut-off values compared to the manufacturer suggested cut-off values resulted in 1 and 39 fewer samples for aβ2GPI and aCL to be classified as positive for aPL, respectively. Conclusions We present Phadia/EliA cut-off values with 90% CI for aPL determined systematically according to the ISTH and CLSI guidelines. These values are different from values previously determined, suggesting variation of aPLs in different populations. Our findings indicate the need for each laboratory to determine/validate assay specific cut-off values for aPL.

scholarly journals AB0080 ALTERED CONCENTRATIONS OF DIFFERENT SMALL EXTRACELLULAR VESICLE POPULATIONS IN PLASMA OF PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1069.3-1070
Author(s):  
U. Stok ◽  
A. Shephard ◽  
S. Cucnik ◽  
S. Sodin-Šemrl ◽  
P. Zigon
Keyword(s):  
Adhesion Molecules ◽  
Antiphospholipid Syndrome ◽  
Whole Blood ◽  
Antiphospholipid Antibodies ◽  
Blood Donors ◽  
Autoimmune Disorder ◽  
Study Groups ◽  
Extracellular Vesicle ◽  
Small Population ◽  
Mean Size

Background:Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombosis, obstetric complications, and the presence of antiphospholipid antibodies (aPL) that cause endothelial injury and thrombophilia [1]. Extracellular vesicles (EVs) are involved in various thrombotic disorders [2], including APS [3, 4], and therefore may influence the prothrombotic status of APS patients. One of the hallmarks of activated endothelium is the expression of adhesion molecules, such as ICAM-1 (CD54) and E-selectin (CD62E), that play a key function in the interactions with leukocytes and platelets.Objectives:To determine the level of total tetraspanin (CD81/CD63/CD9)-positive vesicles and specific EV populations (CD54- and CD62E-positive EVs) in plasma from APS patients.Methods:Whole blood was collected from 4 APS patients and 3 healthy blood donors (HBDs) and processed to obtain platelet-depleted plasma. The size and concentration of EVs were determined using ExoView platform (NanoView Biosciences, MA, USA). In brief, EVs were captured and immobilized on ExoView Tetraspanin chips using the capture antibodies CD81, CD63, and CD9. Size was determined using SP-IRIS technology. Concentration measurements were performed with fluorescently labeled detection antibodies, specifically tetraspanins (CD81/CD63/CD9) for total EVs and CD54 and CD62E for specific EV populations.Results:Analysis of EVs size confirmed the presence of small EVs (sEVs, < 70 nm) in both study groups. The size of EVs did not vary significantly between study groups (mean size ± SD in APS vs. HBD; CD81 (63.1 ± 1.5 nm vs. 66.6 ± 10.6 nm), CD63 (63.3 ± 1.64 nm vs. 69.2 ± 13.2 nm), and CD9 capture spot (61.8 ± 1.18 nm vs. 64.1 ± 7.64 nm)). The levels of total EVs (tetraspanin-positive) were increased 1.7-fold, 1.4-fold, and 2.2-fold for CD81, CD63, and CD9 capture spots, respectively, in APS patients compared to HBDs (Figure 1A). In addition, CD54- and CD62E-positive EVs represented a small population (< 2 %) of the total EVs (Figure 1B). The levels of CD54 were increased 2.9-fold, 3.0-fold, and 2.5-fold on CD81, CD63, and CD9 capture spots, respectively, and similarly, the levels of CD62E were increased 2.2-fold, 2.7-fold, and 2.0-fold on CD81, CD63, and CD9 capture spots, respectively, in APS patients compared to HBDs (Figure 1A).Figure 1.Concentration of tetraspanin- (CD81/CD63/CD9), CD54- and CD62- positive sEVs in APS patients and HBDs.Conclusion:Higher levels of sEVs and increased percentage of CD54- and CD62E-positive sEVs in plasma of APS patients could indicate an altered and activated endothelium in those patients.References:[1]Miyakis S. Journal of thrombosis and haemostasis. 2006.[2]Zara M. Int J Mol Sci. 2019.[3]Chaturvedi S. Semin Thromb Hemost. 2018.[4]Stok U. Cells. 2020.[5]Oggero S. Front Pharmacol. 2019.Disclosure of Interests:Ula Stok: None declared, Alex Shephard Employee of: NanoView Biosciences., Sasa Cucnik: None declared, Snežna Sodin-Šemrl: None declared, Polona Zigon: None declared

Behavioural risk factors for HIV infection amongst blood donors in London

1996 ◽  
Vol 6 (1) ◽  
pp. 31-36 ◽  
Author(s):  
F. M. Cowan ◽  
A. M. Johnson ◽  
J. Wadsworth ◽  
M. Brennan
Keyword(s):  
Risk Factors ◽  
Hiv Infection ◽  
Blood Donors ◽  
Behavioural Risk Factors

Frequency of RHD variants in serologically weak D Turkish blood donors

2020 ◽  
pp. 103024
Author(s):  
Melek Yanasik ◽  
Fatma Savran Oguz ◽  
Sevgi Kalayoglu Besisik ◽  
Mukadder Huslu ◽  
Gulyuz Ozturk ◽  
...  
Keyword(s):  
Blood Donors
Sign in / Sign up

Export Citation Format

Share Document